Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome
FCS is a rare and debilitating genetic disease often leading to significant risk of acute, potentially fatal pancreatitis If approved, olezarsen would be the first approved treatment for FCS in the U.S. CARLSBAD, Calif., Jan. 31, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq:…
Comments Off on Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome